This document is a summary of qualifications from Qing Min. It outlines their educational background receiving a Ph.D from Wuhan Institute of Virology in 2011, focusing on antiviral drug development. It also details work experience at Novartis and Merck developing assays and biomarkers for clinical trials. Special skills include experience with molecular biology techniques such as sequencing, replicon systems, and assay development for antiviral screening and biomarker analysis.

1. To whom it may Concern,
Summary
I am a native of Hunan where I received my undergraduate education. I moved to
Wuhan Institute of virology, Chinese Academy of Science where I completed my Ph.D.
in 2011. My dissertation focused on assay development for selection of novel inhibitors
for Dengue and West Nile virus, characterization of the mode of action of interested
compound on inhibitory of virus infection, Identification targets of antiviral agents and
using Virus-like particles for dengue diagnosis and vaccine development. During my
study, I was selected as an exchange scientist and was trained at the Department of
Health, State of New York, USA and the Novartis Institute for Tropical Diseases Pte
Ltd, Singapore for three-and-a-half years on in vitro and in vivo virology systems. I
published more than 20 papers, 5 of them as first author, in peer-reviewed journals
including Journal of Virology and Antiviral Research.
My first job (2011 – 2012) was Research Scientist (Level I) at the Novartis Institutes
for BioMedical Research Co., Ltd. (CNIBR) in Shanghai. I acquired extensive
knowledge and hands on experience in the areas of tumor biology, enzymatic assay
development, high throughput screening and compound profiling.
In order to further develop my skill sets and expand my knowledge base in clinical and
translational medicine, I joined Merck Serono China as a Senior Scientist to provide
pharmacokinetics and biomarker support to Asian clinical trials and global preclinical
programs. During my 3 year tenure, I managed a team of scientists on method
development, method validation and sample analyses of novel tumor biomarkers,
including PD-L1 and other checkpoint inhibitors, EGFR/Her2/Her3/Her4, RAS, cMet,
integrins, cytokines and hypoxia markers, using next generation sequencing, gene
expression, ELISA as well as immunohistochemistry. As a Study Director, I
communicated directly with global colleagues by regular emails, teleconferences and
face-to-face meetings. Besides management of a team of scientists to perform method
validation and sample analysis, I also communicated with finance and vendors to make
the budget and arranged reagents and clinical/preclinical sample delivery before
initiation of the projects. In addition, I assisted the vendor to arrange the logistics for
importation of clinical and preclinical human samples as well as biological assay
reagents into China. For outsourcing project, performed due diligence and identified
the correct CRO, and monitor the CRO to perform method transfer/development and
sample analysis. For biomarker analyses. I am proficient in industrial/regulatory
policies and guidelines (FDA, CFDA).
Specialskills and competence
Experience with molecular and cellular biology.
1. Experience with sequencing technology including both viral geneome construction
(11 kb) and data analysis, such as RNA-SEQ and DNA-SEQ.
2. Construction of DENV infectious clone and DENV-Replicon.

2. 3. Construction and establishment of flavivirus viral like particles system for
diagnosis and HTS.
4. Reporter-harboring replicon cell line selection
5. Analysis of RNA –protein, protein-protein interaction by Co-immunoprecipitation
(Co-IP), RT-PCR, western blot, Fluorescence spectroscopy and IFA (Confocal
microscope).
6. Experience with protein purification using HPLC.
7. Experience with culture of BHK-21, Vero, LLCMK-2, Huh-7, Huh-7.5, A549,
293T and C6/36 cells (Electroporation of infectious RNA to these cell lines and
monitor the RNA copies and renilla luciferase activity by Real-time RT- PCR and
luminescence signal)
8. Identify host proteins involved in dengue infection by SiRNA approach in A549
cells and Huh-7.5 cells.
9. Determination of virus titer by plaque assay on Vero cells and BHK-21 cells.
10. Selection of escape mutant virus on Vero cells and BHK-21 cells.
Experience in drug discovery in cell-based assay.
1. Development of reporting replicon cell-based HTS assay for drug discovery.
2. Virus-like particles assay for compounds high-throughput screening in different
cell line.
3. TSV01 Reporting virus for compounds high-throughput screening in different cell
line.
4. Familiar with Cytotoxicity assays: Tested by MTT or Cell-titer Glo.
Experience in drug discovery in biochemical assay.
1. Experience with LCMS, HTRF and Coupled assay.
2. Experience with MOA study of inhibitors.
3. Extensive experience on data analysis tools such as Excel, Prism, Spotfire, Helios.
Experience in biomarker assay development, validation and sample analysis.
1. Development of several NGS mutation analysis assay(customized gene panel),
gene expression assay and immunohistochemistry assay.
2. Extensive experience on preclinical and clinical sample analysis in GLP lab.
3. Extensive experience on preparation of study plan and study report for clinical trial
study.
I am looking forward to your contact.
Best,
Qing Min
18610933421